Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction: A randomized pilot study
Main finding · Major adverse cardiac and cerebral events (MACCE)Result — go to the resultHazard ratio 1.54 95% CI 0.26–9.24Authors' conclusion
Although no significant difference in ischemic events was observed between the novel concept of ticagrelor monotherapy and DAPT, safety cannot be confirmed given the small number of events. Additionally, there was a tendency for a reduction in clinically relevant non-access site bleeding events.
Study context
- Population
- ST-elevation myocardial infarction (STEMI) patients directly after primary percutaneous coronary intervention (PCI)STEMI patients randomized
- Participants
- 200 participants
- Comparison
- Ticagrelor monotherapy versus ticagrelor plus aspirin, directly after primary PCI
- Experimental groupn = 99
- Control groupn = 101reference
- Outcome
- Major adverse cardiac and cerebral events (MACCE)
- Follow-up
- 3 months
Methodological details1:1 randomized
- 1:1 randomized
Main finding
As reported in the abstract
Hazard ratio
1.54
95% CI 0.26–9.24
By group
Experimental groupvs control group
HR 1.54 (95% CI 0.26–9.24)
Safety
| Outcome | Experimental group | Control group | HR (95% CI) | |
|---|---|---|---|---|
| Clinically relevant bleeding · 3 months | 4.2% | 8.9% | 0.46 (0.14–1.48) | |
| Clinically relevant non-access site bleeding · 3 months | 2.0% | 7.9% | 0.25 (0.05–1.19) | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction: A randomized pilot study. Am Heart J. Published 28 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →